帕罗西汀联合奥氮平对抑郁症并发睡眠障碍患者心理状态及睡眠质量的影响

目的探讨帕罗西汀联合奥氮平对抑郁症并发睡眠障碍患者心理状态及睡眠质量的影响。方法选取2018年1月至2019年12月就诊于深圳市龙华区慢性病防治中心的抑郁症并发睡眠障碍患者68例作为研究对象,按随机数字表法分为对照组与观察组,各34例。对照组予以帕罗西汀治疗,观察组加用奥氮平治疗。比较两组临床疗效、汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评分、睡眠质量和不良反应发生情况。结果观察组治疗有效率为94.12%,高于对照组的76.47%,差异有统计学意义(P<0.05);治疗后观察组HAMD、HAMA评分为(9.13±1.25)分、(8.15±1.03)分,低于对照组的(12.25±1.86)分、(10.89±1.57)分,差异有统计学意义(P<0.05);观察组治疗后匹兹堡睡眠质量指数(PSQI)评分为(5.36±1.01)分,低于对照组的(7.05±1.35)分,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论帕罗西汀联合奥氮平可提高抑郁症并发睡眠障碍患者治疗效果,减轻抑郁和焦虑症状,改善睡眠质量,安全可靠。

Influence of Paroxetine Combined with Olanzapine on Mental State and Sleep Quality in Patients with Depression and Sleep Disorder

Objective To analyze influence of paroxetine combined with olanzapine on mental state and sleep quality in patients with depression and sleep disorder. Methods A total of 68 patients with depression complicated with sleep disorder admitted to Longhua District Center for Chronic Disease Control of Shenzhen from January 2018 to December 2019 were selected as the research subjects and were divided into a control group and an observation according to the random number table, with 34 patients in each group. The control group was treated with paroxetine, while the observation group was treated with paroxetine plus olanzapine. Clinical efficacy, Hamilton Depression Scale(HAMD) score, Hamilton Anxiety Scale(HAMA) score, sleep quality and adverse reactions of the 2 groups were compared. Results The total effective rate of the observation group(94.12%) was higher than that of the control group(76.47%), the difference was statistically significant(P<0.05). After treatment, the scores of HAMD and HAMA in the observation group were (9.13±1.25) points,(8.15±1.03) points], lower than those in the control group (12.25±1.86) points,(10.89±1.57) points], with statistically significant difference(P<0.05);the score of Pittsburgh sleep quality index(PSQI) in the observation group (5.36±1.01) points] was lower than that in the control group (7.05±1.35) points], with statistically significant difference(P<0.05);no serious adverse reactions were found in the 2 groups, the difference was not statistically significant(P>0.05). Conclusion Paroxetine combined with olanzapine in treatment of patients with depression and sleep disorder can improve the curative effects, alleviate depression and anxiety, and enhance sleep quality, which is safe and reliable.